<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02052544</url>
  </required_header>
  <id_info>
    <org_study_id>PICT-01</org_study_id>
    <nct_id>NCT02052544</nct_id>
  </id_info>
  <brief_title>Clinical Performance Evaluation of Pefakit® PiCT® UC In Vitro Diagnostic Medical Device</brief_title>
  <official_title>Clinical Performance Evaluation of Pefakit® PiCT® UC In Vitro Diagnostic Medical Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DSM Nutritional Products, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DSM Nutritional Products, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the substantial equivalence (SE) of Pefakit® PiCT® UC (test device, T) to
      aPTT-SP (Hemosil) (predicate device, P) in determining heparin levels in subjects undergoing
      heparin therapy in support of a United States Food and Drug Administration (FDA) 510(k)
      submission.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Standard of Care Study. Objective is to monitor the patients' heparin levels under treatment
      with continuous unfractionated heparin infusions. Blood samples collections (4 ml) are
      required routinely. A proportion of this standard sample (leftover plasma) will be used for
      study purposes. About three samples will be analyzed which are collected within 2 - 4 days.
      Time points for blood sample collections will be defined by the treating physician according
      the local standard of care and will be associated exclusively to clinical considerations.
      Results of the Pefakit® PiCT® UC assay will NOT be used to take therapeutic decisions for
      study subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Sensitivity and Specificity of Pefakit and Hemosil.</measure>
    <time_frame>within 2 - 4 days</time_frame>
    <description>Sensitivity is the proportion of positive cases identified as positive. Specificity is the proportion of negative cases identified as negative. The Sensitivity and Specificity of Pefakit and Hemosil were calculated for the overall study population and separately for each of the three medical centers. Sensitivity and Specificity of Pefakit and Hemosil were each assessed relative to the reference method (Biophen)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">123</enrollment>
  <condition>Thromboembolic Events</condition>
  <arm_group>
    <arm_group_label>Study patients</arm_group_label>
    <description>Patients receiving unfractionated heparin (UFH)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects undergoing UFH anticoagulation therapy will are needed for this study. Typically,
        such patients are undergoing cardiovascular surgery, are being treated for thromboembolic
        events, or are receiving heparin intravenously for thrombosis prophylaxis due to its more
        advantageous pharmacokinetic profile in some situations.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects receiving a continuous infusion with UFH

          -  Subjects who have given written informed consent (unless written informed consent is
             waived by local regulations or local EC/IRB)

        Exclusion Criteria:

          -  Subjects treated with any other anticoagulants other than UFH

          -  Subjects who have been undergoing fibrinolytic therapy within the previous 4 weeks

          -  Subjects who are known to have a congenital bleeding disorder

          -  Subjects known to present unexplained prolongations of clotting time

          -  Subjects known to have coagulation factor deficiencies

          -  Patient participating or who has participated within one month from enrolment in
             another investigational study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Korte</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deputy Head Institute for Clinical Chemistry and Hematology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manuela K. Krause, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsche Klinik für Diagnostik GmbH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rathbun Suman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oklahoma Health Sciences Center- Department of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsche Klinik für Diagnostik</name>
      <address>
        <city>Wiesbaden</city>
        <state>Hessen</state>
        <zip>65191</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cantonal Hospital -Institue for Clinical Chemistry and hematology</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2014</study_first_submitted>
  <study_first_submitted_qc>January 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2014</study_first_posted>
  <results_first_submitted>February 27, 2015</results_first_submitted>
  <results_first_submitted_qc>May 4, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 6, 2015</results_first_posted>
  <last_update_submitted>May 4, 2015</last_update_submitted>
  <last_update_submitted_qc>May 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>determination of heparin levels</keyword>
  <keyword>Patients</keyword>
  <keyword>requiring</keyword>
  <keyword>unfractionated</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>FPI: Jul 2012; LPO May 2013
All three centers were hospitals (medical clinics) with certified laboratory.</recruitment_details>
      <pre_assignment_details>Plasma from subjects treated with any other anticoagulants other than UFH. Plasma from subjects who have been undergoing fibrinolytic therapy within the previous 4 weeks.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Study Patients</title>
          <description>Patients receiving unfractionated heparin (UFH)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="123">First Subject In</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="123">Last Subject Out</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>144 subjects signed ICF. 4 out of 144 failed in/exclusion criteria 123 subjets are part of the AVS (all valid subjects) population. All 123 UFH treated study subjects had previous and concomitant medications and treatments.</population>
      <group_list>
        <group group_id="B1">
          <title>Plasma Samples From Subjects Receiving Unfractionated Heparin</title>
          <description>A total of 123 valid patients were recruited over three clinical centers (two in Europe, one in the US). The patients were selected from subjects receiving UFH therapy and who have given written informed consent. Excluded from the study were subjects treated with any other anticoagulants other than UFH, subjects who have been undergoing fibrinolytic therapy within the previous 4 weeks, subjects known to have a congenital bleeding disorder, subjects known to show coagulation factor deficiencies and subjects known to have a coagulation inhibitor or an unexplained APTT prolongation.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="123"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.5" lower_limit="18" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>partecipants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Oriental</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Sensitivity and Specificity of Pefakit and Hemosil.</title>
        <description>Sensitivity is the proportion of positive cases identified as positive. Specificity is the proportion of negative cases identified as negative. The Sensitivity and Specificity of Pefakit and Hemosil were calculated for the overall study population and separately for each of the three medical centers. Sensitivity and Specificity of Pefakit and Hemosil were each assessed relative to the reference method (Biophen)</description>
        <time_frame>within 2 - 4 days</time_frame>
        <population>AVS (all valid subjects) population: All valid subjects with no major deviation affecting outcome.413 samples total analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Pefakit</title>
            <description>Sensitivity and Specificity of Pefakit</description>
          </group>
          <group group_id="O2">
            <title>Hemosil</title>
            <description>Sensitivity and Specificity of Hemosil</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Sensitivity and Specificity of Pefakit and Hemosil.</title>
          <description>Sensitivity is the proportion of positive cases identified as positive. Specificity is the proportion of negative cases identified as negative. The Sensitivity and Specificity of Pefakit and Hemosil were calculated for the overall study population and separately for each of the three medical centers. Sensitivity and Specificity of Pefakit and Hemosil were each assessed relative to the reference method (Biophen)</description>
          <population>AVS (all valid subjects) population: All valid subjects with no major deviation affecting outcome.413 samples total analyzed</population>
          <units>percentage of cases</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall Sensitivity%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3" lower_limit="75.7" upper_limit="89.4"/>
                    <measurement group_id="O2" value="77" lower_limit="68.6" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall Specificity%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.5" lower_limit="68.6" upper_limit="90.7"/>
                    <measurement group_id="O2" value="59.3" lower_limit="45" upper_limit="72.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>site #1 (St.Gallen) Sensitivity%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.6" lower_limit="79.3" upper_limit="96.9"/>
                    <measurement group_id="O2" value="94.3" lower_limit="84.3" upper_limit="98.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>site #1 (St.Gallen) Specificity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.7" lower_limit="39" upper_limit="94"/>
                    <measurement group_id="O2" value="27.3" lower_limit="6" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>site #2 (Wiesbaden) Sensitivity%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.4" lower_limit="58.8" upper_limit="86.5"/>
                    <measurement group_id="O2" value="53.5" lower_limit="37.7" upper_limit="68.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>site #2 (Wiesbaden) Specificity%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.3" lower_limit="56.3" upper_limit="92.5"/>
                    <measurement group_id="O2" value="69.6" lower_limit="47.1" upper_limit="86.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>site #3 (Oklahoma) Sensitivity%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3" lower_limit="65.3" upper_limit="94.4"/>
                    <measurement group_id="O2" value="80" lower_limit="61.4" upper_limit="92.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>site #3 (Oklahoma) Specificity%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="68.3" upper_limit="98.8"/>
                    <measurement group_id="O2" value="65" lower_limit="40.8" upper_limit="84.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the date of FPI (first patient in) until LPO (last patient out).</time_frame>
      <desc>In the US the study meets the requirements for exemption as defined in the Investigational Device Exemption regulations (21 CFR Part 812.2(c)).
In the EU, national regulations were followed regarding adverse event reporting for IVD studies.</desc>
      <group_list>
        <group group_id="E1">
          <title>Study Patients</title>
          <description>Patients receiving unfractionated heparin (UFH)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any proposed publication, lecture, manuscript, poster presentation or other disclosure or dissemination of the data or Results of this study by PI shall be submitted to DSM at least forty-five (45) days prior to its submission for publication or use for DSM’s review, comment and approval. DSM reserves the right to have deleted from the proposed text all of DSM’s Confidential Information which may be contained therein. DSM’s comments shall be provided without undue delay.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anne Brisset</name_or_title>
      <organization>DSM Nutritional Products Ltd Branch Pentapharm</organization>
      <phone>41 61 706 4837</phone>
      <email>Anne.Brisset@pentapharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

